METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Clinical trials for METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA trials appear
Sign up with your email to follow new studies for METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boost may slow rare sarcomas
Disease control Recruiting nowThis phase 3 trial tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (doxorubicin) helps people with advanced or spreading sarcomas live longer without their cancer getting worse. About 365 adults with specific sarcoma types will be randomly assi…
Matched conditions: METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-phase trial tests whether combining two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—is safe and effective for people with advanced sarcomas that have spread or can't be removed by surgery. About 30 adults with specific sarcoma types will receiv…
Matched conditions: METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC